An interventional study of Medication for Opioid Use Disorder and MISSION Critical Time Intervention in Opioid Use Disorder and Mental Health Disorder, sponsored by University of Massachusetts, Worcester. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by University of Massachusetts, Worcester · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,223 studies in Opioid-Related Disorders with a site in United States — 246 open to participants now, 316 under way, 18 of them phase 3. Opioid-Related Disorders · United States.
Among the 1,223 studies in Opioid-Related Disorders with a site in United States, this one is the 45th largest by planned enrollment of the 1,098 interventional ones that give a count, is one of 83 that started in 2022, is one of 571 with no phase, reaches primary completion later than 175 of the 315 other live ones, and was the 792nd registered.
1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
Browse Opioid-Related Disorders studies →246 of the 1,223 studies in Opioid-Related Disorders with a site in United States are open now. Recruiting first, the newest first:
Washington State University · Sites in United States
Ages 18+
University of Massachusetts, Worcester · Sites in United States
Ages 18+ · Healthy volunteers
Ohio State University · Sites in United States
Ages 21–65
University of Kentucky · Sites in United States
Ages 18–75
Baylor College of Medicine · Sites in United States
Ages 18–64
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,223 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 162 · Phase 2 245 · Phase 3 99 · Phase 4 79
First in 1988; this study’s year is marked. 83 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.
Median enrollment 56 across the 1,098 interventional studies, 85 across the 122 observational. Of the 834 that completed or were terminated, 332 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
132 of 1,223 have an industry lead sponsor. The 10 most frequent:
University of Massachusetts, Worcester is the lead sponsor of 291 studies on the registry; 50 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
University of Massachusetts, Worcester has 3 studies filed under Opioid-Related Disorders — fewer than ten, so there is no comparison to draw.
129 of the studies in Opioid-Related Disorders with a site in United States that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05011266Phase 3New York State Psychiatric InstituteEfficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder | 2027-01-01 |
| NCT05834478Phase 3Emory UniversityNon-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3 | 2027-02 |
| NCT05033028Phase 3NYU Langone HealthSmartphones for Opiate Addiction Recovery | 2027-06-01 |
| NCT05459402Phase 3University of Maryland, BaltimoreDivided or Single Exposure (DOSE) Study | 2027-06-01 |
| NCT05766631Phase 3Friends Research Institute, Inc.Treating Polysubstance Use Using a Novel Digital Technology | 2027-06-30 |
Add all 129 to your calendar (.ics) → With an account.
Among the 1,223 studies in Opioid-Related Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This 4-year study will randomize 1,000 people with co-occurring opioid use and mental health disorders (COD) at medication for opioid use disorder (MOUD) clinics to evaluate the effectiveness of MISSION, a multi-component team approach, or its components with MOUD versus MOUD alone, as well as the incremental benefits of MISSION or its components for improving outcomes. We expect that individuals receiving MISSION or its parts + MOUD will show greater improvement over MOUD alone on: engagement, substance use, and mental health.
This is a 5-arm randomized control trial with a fractional factorial design among 1,000 patients across Massachusetts. Patients will be randomized to: 1) MOUD alone; 2) full MISSION (CTI \& DRT \& PS) + MOUD; 3) CTI \& DRT + MOUD; 4) PS \& DRT + MOUD; or 5) CTI \& PS + MOUD (Arms 3-5 are the 3 combinations of 2 MISSION parts). MISSION is a time-limited, cross disciplinary, team-based wraparound approach that provides 6 months of psychosocial treatment combined with assertive outreach, empowering clients to access and engage in care and community services to promote recovery. The MISSION treatment curriculum integrates 3 evidence-based practices along with MOUD: 1) Critical Time Intervention (CTI), a time-limited form of assertive community treatment; 2) Dual Recovery Therapy (DRT), which is integrated mental health and substance use group therapy; and 3) Peer Support (PS), offering support for people in recovery by people in recovery. Participants will receive 6 months of treatment and be followed for 1-year.
Study aims include:
Aim 1: To evaluate the effectiveness of MISSION or its bundled parts with MOUD versus MOUD alone, as well as the incremental benefits of MISSION and its parts + MOUD to improve outcomes 1a-c for CODs.
Hypothesis 1.1: Individuals receiving MISSION or its parts + MOUD will show greater improvement over MOUD alone on: 1a. Engagement (measured by total days in treatment, percentage of days receiving MOUD, and total number of outreach and linkages sessions); 1b. Opioid use and other substance use (measured by self-report days of use and drug screens); and 1c. Mental health (measured by self-report mental health symptoms).
Hypothesis 1.2: MISSION + MOUD will outperform its parts + MOUD but at least one of the three combinations + MOUD will be at least 75% as effective compared to the full MISSION protocol on outcomes 1a-c.
Aim 2: To examine mechanisms of action of MISSION in CODs. Hypothesis 2.1: The effects of MISSION and its bundled parts on health outcomes (mental health, opioid and other substance use) are mediated by treatment participation and other measures (e.g., recovery capital, psychosocial supports, and quality of life). Hypothesis 2.2: The effects of MISSION and its parts on health outcomes are moderated by key patient characteristics (e.g., demographics, severity of COD, and MOUD type).
Aim 3: To conduct a comprehensive economic evaluation of MISSION or its bundled parts and MOUD.
Estimate cost of full MISSION or its bundled parts compared to MOUD alone, and to evaluate cost-effectiveness and return on investment from multiple perspectives, including patient, clinic, healthcare, taxpayer, and societal.
Exploratory Aim: 4. To construct a predictive model that can match optimum combined use of MISSION parts with specific patient's needs for greater improvements in health outcomes, which will inform a future randomized controlled trial on cost-effective patient-level precision intervention assignment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTI + DRT + PS + MOUD
Other: Medication for Opioid Use Disorder · Behavioral: MISSION Critical Time Intervention · Behavioral: MISSION Peer Support · Behavioral: MISSION Dual Recovery Therapy
CTI + DRT + MOUD
Other: Medication for Opioid Use Disorder · Behavioral: MISSION Critical Time Intervention · Behavioral: MISSION Dual Recovery Therapy
CTI + PS + MOUD
Other: Medication for Opioid Use Disorder · Behavioral: MISSION Critical Time Intervention · Behavioral: MISSION Peer Support
DRT + PS + MOUD
Other: Medication for Opioid Use Disorder · Behavioral: MISSION Peer Support · Behavioral: MISSION Dual Recovery Therapy
MOUD
Other: Medication for Opioid Use Disorder
medication management
Also known as: MOUD
offering intensive community-based services that decrease in intensity over time
Also known as: CTI
including 11 recovery-oriented sessions from someone with lived experience of co-occurring disorders
Also known as: PS
comprised of 13 structured co-occurring disorders treatment sessions
Also known as: DRT
Engagement in treatment
Measured by total days in treatment
Time frame: 6 months
Engagement in medication for opioid use disorder (MOUD)
Measured by percentage of days receiving MOUD
Time frame: 6 months
Engagement in outreach and linkage sessions
Measured by total number of outreach and linkage sessions
Time frame: 6 months
Self-report opioid use and other substance use
Measured by self-report days of use
Time frame: Baseline
Self-report opioid use and other substance use
Measured by self-report days of use
Time frame: 3 months
Self-report opioid use and other substance use
Measured by self-report days of use
Time frame: 6 months
Self-report opioid use and other substance use
Measured by self-report days of use
Time frame: 9 months
Self-report opioid use and other substance use
Measured by self-report days of use
Time frame: 12 months
Opioid use and other substance use (drug screen)
Measured by positive drug screens
Time frame: 3 months
Opioid use and other substance use (drug screen)
Measured by positive drug screens
Time frame: 6 months
Mental health functioning
Measured by self-report mental health symptoms on Behavior and Symptom Identification Scale (BASIS-24)
Time frame: Baseline
Mental health functioning
Measured by self-report mental health symptoms on BASIS-24
Time frame: 3 months
Mental health functioning
Measured by self-report mental health symptoms on BASIS-24
Time frame: 6 months
Mental health functioning
Measured by self-report mental health symptoms on BASIS-24
Time frame: 9 months
Mental health functioning
Measured by self-report mental health symptoms on BASIS-24
Time frame: 12 months
PTSD symptoms
Measured by self-report PTSD symptoms on Patient Checklist (PCL-5)
Time frame: Baseline
PTSD symptoms
Measured by self-report PTSD symptoms on Patient Checklist (PCL-5)
Time frame: 3 months
PTSD symptoms
Measured by self-report PTSD symptoms on Patient Checklist (PCL-5)
Time frame: 6 months
PTSD symptoms
Measured by self-report PTSD symptoms on Patient Checklist (PCL-5)
Time frame: 9 months
PTSD symptoms
Measured by self-report PTSD symptoms on Patient Checklist (PCL-5)
Time frame: 12 months
Mental health impairment
Measured by self-report on World Health Organization Disability Assessment (WHODAS 2.0)
Time frame: Baseline
Mental health impairment
Measured by self-report on WHODAS 2.0
Time frame: 3 months
Mental health impairment
Measured by self-report on WHODAS 2.0
Time frame: 6 months
Mental health impairment
Measured by self-report on WHODAS 2.0
Time frame: 9 months
Mental health impairment
Measured by self-report on WHODAS 2.0
Time frame: 12 months
Psychiatric severity
Measured by Structured Clinical Interview for DSM-5 (SCID-RV)
Time frame: Baseline
Health functioning
Measured by the World Health Organization Quality of Life Scale Brief Version (WHOQOL-BREF)
Time frame: Baseline
Health functioning
Measured by the WHOQOL-BREF
Time frame: 3 months
Health functioning
Measured by the WHOQOL-BREF
Time frame: 6 months
Health functioning
Measured by the WHOQOL-BREF
Time frame: 9 months
Health functioning
Measured by the WHOQOL-BREF
Time frame: 12 months
Motivation for treatment
Measured by Stages of Change, Readiness, and Treatment Eagerness Scale (SOCRATES)
Time frame: Baseline
Motivation for treatment
Measured by SOCRATES
Time frame: 3 months
Motivation for treatment
Measured by SOCRATES
Time frame: 6 months
Motivation for treatment
Measured by SOCRATES
Time frame: 9 months
Motivation for treatment
Measured by SOCRATES
Time frame: 12 months
Suicide Severity
Measured by Columbia- Suicide Severity Rating Scale (C-SSRS)
Time frame: Baseline
Suicide Severity
Measured by C-SSRS
Time frame: 3 months
Suicide Severity
Measured by C-SSRS
Time frame: 6 months
Suicide Severity
Measured by C-SSRS
Time frame: 9 months
Suicide Severity
Measured by C-SSRS
Time frame: 12 months
Therapeutic alliance
Measured by Working Alliance Inventory
Time frame: Baseline
Therapeutic alliance
Measured by Working Alliance Inventory
Time frame: 3 months
Therapeutic alliance
Measured by Working Alliance Inventory
Time frame: 6 months
Therapeutic alliance
Measured by Working Alliance Inventory
Time frame: 9 months
Therapeutic alliance
Measured by Working Alliance Inventory
Time frame: 12 months
Recovery Capital
Measured by Assessment of Recovery Capital
Time frame: Baseline
Recovery Capital
Measured by Assessment of Recovery Capital
Time frame: 3 months
Recovery Capital
Measured by Assessment of Recovery Capital
Time frame: 6 months
Recovery Capital
Measured by Assessment of Recovery Capital
Time frame: 9 months
Recovery Capital
Measured by Assessment of Recovery Capital
Time frame: 12 months
Chronic pain
Measured by Chronic Pain assessment
Time frame: Baseline
Chronic pain
Measured by Chronic Pain assessment
Time frame: 3 months
Chronic pain
Measured by Chronic Pain assessment
Time frame: 6 months
Chronic pain
Measured by Chronic Pain assessment
Time frame: 9 months
Chronic pain
Measured by Chronic Pain assessment
Time frame: 12 months
Medication Adherence
Measured by Medication Adherence Rating Scale
Time frame: 3 months
Medication Adherence
Measured by Medication Adherence Rating Scale
Time frame: 6 months
Mortality
Data extracted from medical records
Time frame: 6 months
Quality Adjusted Life Years (QALYs): health
Measured by self-report on the 5-level EQ-5D (EQ-5D-5L). Scores range from 0 (worst imaginable health) to 100 (best imaginable health).
Time frame: Baseline
Quality Adjusted Life Years (QALYs): health
Measured by self-report on the 5-level EQ-5D (EQ-5D-5L). Scores range from 0 (worst imaginable health) to 100 (best imaginable health).
Time frame: 3 months
Quality Adjusted Life Years (QALYs): health
Measured by self-report on the 5-level EQ-5D (EQ-5D-5L). Scores range from 0 (worst imaginable health) to 100 (best imaginable health).
Time frame: 6 months
Quality Adjusted Life Years (QALYs): health
Measured by self-report on the 5-level EQ-5D (EQ-5D-5L). Scores range from 0 (worst imaginable health) to 100 (best imaginable health).
Time frame: 9 months
Quality Adjusted Life Years (QALYs): health
Measured by self-report on the 5-level EQ-5D (EQ-5D-5L). Scores range from 0 (worst imaginable health) to 100 (best imaginable health).
Time frame: 12 months
Quality Adjusted Life Years (QALYs): quality of life
Measured by self-report on Patient Reported Outcomes - Preference (PROPr). Scores range from 0 to 100 with higher scores indicating worse quality of life.
Time frame: Baseline
Quality Adjusted Life Years (QALYs): quality of life
Measured by self-report on Patient Reported Outcomes - Preference (PROPr). Scores range from 0 to 100 with higher scores indicating worse quality of life.
Time frame: 3 months
Quality Adjusted Life Years (QALYs): quality of life
Measured by self-report on Patient Reported Outcomes - Preference (PROPr). Scores range from 0 to 100 with higher scores indicating worse quality of life.
Time frame: 6 months
Quality Adjusted Life Years (QALYs): quality of life
Measured by self-report on Patient Reported Outcomes - Preference (PROPr). Scores range from 0 to 100 with higher scores indicating worse quality of life.
Time frame: 9 months
Quality Adjusted Life Years (QALYs): quality of life
Measured by self-report on Patient Reported Outcomes - Preference (PROPr). Scores range from 0 to 100 with higher scores indicating worse quality of life.
Time frame: 12 months
Economic impact of full MISSION
Cost of full MISSION and MOUD measured by Patient-Reported Outcomes Measurement Information System-Preference (PROPr)
Time frame: 6 months
Economic impact of CTI & PS
Cost of MISSION CTI, PS, and MOUD measured by PROPr
Time frame: 6 months
Economic impact of CTI & DRT
Cost of MISSION CTI, DRT, and MOUD measured by PROPr
Time frame: 6 months
Economic impact of PS & DRT
Cost of MISSION PS, DRT, and MOUD measured by PROPr
Time frame: 6 months
Economic impact of MOUD alone
Cost of MOUD alone measured by PROPr
Time frame: 6 months
Plan to share: Yes — Consistent with the NIH HEAL Initiative, Underlying Primary Data collected from participants in this project will be made readily available to the public through twice-yearly submissions to the NIMH Data Archive (NDA). In consultation with the University of Massachusetts Medical School's institutional review board (IRB), project consent forms will include relevant information for participants to be made aware that their de-identified data will be available to other investigators as a part of the HEAL Initiative Public Access and Data Sharing Policy.
Supporting information: Study protocol
Time frame: Data will be available upon publication (via an NDA Study) or 1-2 years after the grant end date (August 2026), until 2032 (expiration of NDA Certificate of Confidentiality)
Access criteria: Data will be shared with authorized NDA users.
Data sharing details ↗ · nda.nih.gov
No publications or documents are linked to this record.
Started Mar 2022 (actual). Primary completion is estimated for Aug 2027, 65 months after the start.
Of 465 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 65 months is above that.
Counting every sponsor, half of 496 studies reached it within 29 months; a quarter within 13 and three quarters within 46.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Aug 2026 → Aug 2027 and completion Aug 2026 → Aug 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Massachusetts, Worcester →